A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorderWilliam B. White, Michael C. Snabes, Deborah Grady et al.|American Heart Journal|2011Cited by 67
Impact of demographic and clinical factors on elagolix plus add-back therapy effects on patient-reported nonbleeding symptoms in women with heavy menstrual bleeding and uterine fibroids: a post hoc analysis of data from two clinical trialsJames A. Simon, Michael C. Snabes, Elizabeth A. Stewart et al.|F&S Reports|2024Cited by 1
Elagolix Improves Low Hemoglobin in Women With Uterine Fibroid-Associated Heavy Menstrual Bleeding: Post Hoc Analysis of Elaris UF-1 and UF-2 [ID: 1368055]Susan Jewell, Liz Uribe, Brett Pinsky et al.|Obstetrics and Gynecology|2023Cited by 0